Aurinia Pharmaceuticals

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aurinia Pharmaceuticals reports robust Q4 earnings and navigates growth challenges

Aurinia Pharmaceuticals had a strong Q4 performance, with revenue growth and patient access milestones. Despite challenges from COVID-19 and legal disputes, the company remains financially stable and focused on driving growth through patient-centric strategies. Opportunities lie in improving patient adherence and expanding market reach.

Aurinia Pharmaceuticals reports strong Q1 performance and eyes global expansion

Aurinia Pharmaceuticals delivered robust financial performance in Q1 2023, with strong revenue growth and positive patient outcomes.
The company's strategic initiatives and globalization efforts position it well for future growth and market expansion.
Challenges such as slowing new patient starts and persistency caution require focused attention for sustained success.
Opportunities lie in enhancing patient engagement, driving revenue through new patient starts, and strengthening competitive positioning.

Aurinia Pharmaceuticals excels in Q2 earnings, eyes growth opportunities

Aurinia Pharmaceuticals delivered strong financial results in Q2 2023, driven by revenue growth, improved commercial metrics, and effective cost management.
The company's focus on patient awareness, clinical differentiation, and market access for LUPKYNIS positions it well in the competitive landscape of lupus nephritis treatment.
While facing challenges such as seasonality impact and strategic uncertainties, Aurinia remains optimistic about its financial stability, pipeline progress, and growth opportunities.

Aurinia Pharmaceuticals reports strong Q3 performance and explores growth

Aurinia Pharmaceuticals demonstrated robust financial performance and strategic partnerships in Q3 2023, positioning itself for future growth.
While facing challenges in persistency rates and strategic decision-making, the company is leveraging upcoming guidelines and data submissions for market advantage.
Opportunities in education, regulatory approvals, and pricing strategies present avenues for sustained growth and market expansion in the lupus nephritis segment.

Aurinia Pharmaceuticals reports strong Q1 earnings and growth opportunities

Aurinia Pharmaceuticals delivered a robust performance in Q1 2024, driven by strong revenue growth and strategic cost management.
While facing challenges in managing expenses and optimizing patient outcomes, the company remains well-positioned for future profitability.
With a focus on expanding market access, enhancing treatment guidelines, and leveraging its financial strength, Aurinia is poised for continued growth and success.

Aurinia Pharmaceuticals reports robust Q2 revenue growth and strategic initiatives

Aurinia Pharmaceuticals delivered strong financial performance in Q2 2024, with notable revenue growth and operational efficiency.
While facing challenges in revenue guidance and market expectations, the company's strategic initiatives and product adoption present growth opportunities.
With a focus on product development, market expansion, and patient engagement, Aurinia is poised for continued success in the pharmaceutical industry.

Aurinia Pharmaceuticals reports robust Q3 earnings and strategic milestones

Aurinia Pharmaceuticals delivered impressive financial results in Q3 2024, showcasing growth in revenue and operational efficiency.
Despite undergoing a significant restructuring, the company remains focused on innovation, achieving milestones, and expanding its market presence.
With a strong cash position and strategic outlook, Aurinia is poised for continued success and growth in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

SEOUL, South Korea--(BUSINESS WIRE)--ILJIN SNT Co., Ltd. ("ILJIN"), one of the largest shareholders of Aurinia Pharmaceuticals (NASDAQ: AUPH) ("Aurinia" or the "Company"), today issued an open letter to fellow shareholders. The full text of the letter is below. ======================= July 11, 2024 Fellow Aurinia Shareholders, Last month, Aurinia (“Company”) announced the voting results of its 2024 annual general meeting of shareholders (“AGM”). The Company announced that four directors -- (i).

ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM

Aurinia Pharmaceuticals stock has dropped more than 80% due to disappointing Lupkynis sales since its launch in 2021. Management is focusing solely on driving Lupkynis sales and cutting costs by laying off 25% of its sales force and discontinuing other programs. With positive cash flow expected soon, a $150 million share repurchase plan, and strong financials, Aurinia is undervalued and worth considering for investment.

Aurinia Pharmaceuticals Appears Undervalued

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Upcoming Investor Healthcare Conferences.

Aurinia to Participate in Upcoming Investor Healthcare Conferences

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces 2024 Annual General Meeting Results.

Aurinia Announces 2024 Annual General Meeting Results

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna, Austria June 12-15. The data reinforces previous findings from the AURORA Clinical Program on the safety and effectiveness of LUPKYNIS® (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adult patients with act.

Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce.

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Provides Update on Proxy Statement.

Aurinia Provides Update on Proxy Statement

GENEVA--(BUSINESS WIRE)--Lucien Selce, who owns approximately 2.2% of the outstanding shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued the following letter to Aurinia shareholders: June 3, 2024 Fellow Shareholders, Ahead of Aurinia's June 14 Annual General Meeting (“AGM”), I am writing to share my concerns regarding the Board of Directors' (the “Board”) anti-shareholder actions and CEO Peter Greenleaf's outsized influence over the current director.

Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf

Amicus Therapeutics

Voyager Therapeutics

Today, we take a look at three promising biotech names that currently trade under $10 a share. Two of these are quickly moving towards profitability, and the other is cash rich and has several partnerships with large pharma companies. We profile all three of these names with favorable risk/reward profiles in the paragraphs below.

3 Biotech Names Under $10 I Own

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Will Attend 2024 Jefferies Global Healthcare Conference.

Aurinia Will Attend 2024 Jefferies Global Healthcare Conference

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18. The Company will also share additional data from its AURORA clinical program. Economic modeling b.

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024.

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%

GENEVA--(BUSINESS WIRE)--Lucien Selce, who owns approximately 2.2% of the outstanding shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued the following letter to Aurinia shareholders: May 7, 2024 Fellow Shareholders, As a shareholder of Aurinia since 2020, I have grown increasingly worried about the Company's trajectory and am disappointed in the Board of Directors' (the “Board”) actions. This is why I now feel dutybound to publicly share my concerns.

Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference.

Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference

AUPH reports Q1'24 net product revenues of $48.1M, representing a 13.6% increase from the previous quarter. AUPH's pipeline member AUR200 has not been shelved and could enter phase 1 studies in 2024 whether in AUPH's hands, or externally if the drug is out-licensed. AUPH bought back 3.4M shares through April 30, at an average price of $5.37 per share.

Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Greg Keenan - Chief Medical Officer Conference Call Participants Farzin Haque - Jefferies Stacy Ku - TD Cowen Joseph Schwartz - Leerink Partners Ed Arce - H.C. Wainwright David Martin - Bloom Burton Operator Greetings, and welcome to the Aurinia Pharmaceuticals First Quarter 2024 Earnings Call.

Aurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call Transcript

Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.18 per share a year ago.

Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS.

Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innovative disease state education campaign for rheumatologists. Aurinia is on a mission to tackle the toughest challenges that the LN community faces thr.

Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month

Aurinia Pharmaceuticals Inc. full-year 2023 sales of Lupkynis increased by 53% year over year to $158.5 million. Updated label provides several advantages for sales of Lupkynis going forward, like no need for monthly kidney monitoring 1-year after treatment, lactation note for women and display of 3-year efficacy. Besides label expansion of Lupkynis, other shareholder generating measures enacted were the $150 million share repurchase program and the cutting of the AUR200 and AUR300 programs to conserve cash.

Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program.

The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program

Aurinia Pharmaceuticals has the potential for up to 80-100% upside by the end of 2024. The company's focus on cost savings and a single product commercial biotech strategy is positive. The potential increase in US sales and from international markets paired with cost savings could make Aurinia cash flow positive by the end of the year.

Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference.

News for Aurinia Pharmaceuticals Stock (AUPH)